Skip Navigation

JNCI Journal of the National Cancer Institute 1993 85(10):812-817; doi:10.1093/jnci/85.10.812
© 1993 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Shapiro, C. L.
Right arrow Articles by Henderson, I. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shapiro, C. L.
Right arrow Articles by Henderson, I. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 85, No. 10, 812-817, May 19, 1993
© 1993 Oxford University Press

Comparison of Adjuvant Chemotherapy With Methotrexate and Fluorouracil With and Without Cyclophosphamide in Breast Cancer Patients With One to Three Positive Axillary Lymph Nodes

Charles L. Shapiro, Rebecca S. Gelman, Daniel F. Hayes, Robert Osteen, Antonio Obando, George P. Canellos, Emil Frei, III, I. Craig Henderson

Breast Evaluation Center and Division of Clinical Oncology, Data-Farber Cancer Institute Boston, Mass.
Department of Biostatistics, Data-Farber Cancer Institute Boston, Mass.
Brigham and Women's Hospital, Harvard Medical School Boston

Correspondence to: Charles L. Shapiro, M.D., Dana-Farber Cancer Institute, Dana 1508, 44 Binney St., Boston, MA 02115.

Background: Alkylating agents administered as single agents or incombination with antimetabolites or anthracyclines delay the appearance of metastases and prolong the survival of breast cancer patients after surgery. Purpose: This phase III clinical trial was designed to evaluate the therapeutic efficacy and toxicity of the alkylating agent cyclophosphamide in combination with the antimetabolites methotrexate and fluorouracil adjuvant to breast cancer surgery. Methods: This study consisted of 255 breast cancer patients (a) with one to three histologically positive axillary lymph nodes and either no detectable primary tumor or operable primary tumors 5 cm or less (T0-T2) (95% of the patients) or (b) with tumors larger than 5 cm (T3) and with negative axillary nodes. Patients were randomly allocated to receive either methotrexate (60 mg/m2) and fluorouracil (600 mg/m2) (MF) intravenously on days 1 and 8 every 28 days for eight cycles or cyclophosphamide (100 mg/m2) orally on days 1–14 plus MF (CMF) every 28 days for the same duration. Median follow-up was 7.8 years, and maximum follow-up was 13 years. Results: There were no statistically significant differences in time to treatment failure or overall survival for patients treated with MF or CMF. At 8 years after completion of treatment, time to treatment failure was 55% (95% confidence interval [CI] = 50%–60%) and 59% (95% CI = 54%–64%) and overall survival was 69% (95% CI = 65%–73%) and 67% (95% CI = 62%–72%) for MF-and CMF-treated patients, respectively. The hazard ratios (MF to CMF) for time to treatment failure and for survival, estimated with a proportional hazards model, were 1.02 (95% CI = 0.69–1.50) and 0.87 (95% CI = 0.56–1.34), respectively. Myelosuppression was significantly greater (P<.0001) in CMF-treated patients during cycles 1–6. Median white blood cell count nadirs were between 4.4 x 103/µL and 3.5 x 103/µL in those receiving CMF. Dose reductions were more frequent in CMF-treated patients, which led to statistically significant differences (P<.0001) in amounts of methotrexate and fluorouracil administered. Primary cancers at other sites occurred in 14 patients (5.5%)—-six treated with MF and eight treated with CMF. Conclusions: Our findings suggest that the addition of cyclophosphamide to adjuvant chemotherapy with MF offers no therapeutic advantage but results in increased myelosuppression. Implications: Future trials will define the possible advantages of antimetabolites in adjuvant therapy. Further information will also become available when results of the ongoing National Surgical Adjuvant Breast and Bowel Project trial comparing adjuvant MF to CMF in node-negative breast cancer patients are presented. [J Natl Cancer Inst 85: 812–817, 1993]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
B. Fisher, J.-H. Jeong, S. Anderson, and N. Wolmark
Treatment of Axillary Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials
J Natl Cancer Inst, December 15, 2004; 96(24): 1823 - 1831.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. A. Franklin, J. Glaspy, S. M. Pflaumer, R. B. Jones, L. Hami, C. Martinez, J. R. Murphy, and E. J. Shpall
Incidence of Tumor-Cell Contamination in Leukapheresis Products of Breast Cancer Patients Mobilized With Stem Cell Factor and Granulocyte Colony-Stimulating Factor (G-CSF) or With G-CSF Alone
Blood, July 1, 1999; 94(1): 340 - 347.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.